Technology | October 07, 2008

AccessClosure’s Mynx Closes Arterial Punctures

The Mynx Vascular Closure Device (VCD) by AccessClosure Inc. closes arterial puncture sites during cardiac catheterization procedures and is designed to minimize the pain historically associated with other closure devices.

The Mynx uses an extravascular, conformable, sponge-like material to seal the puncture site. The sealant material is called polyethylene glycol (PEG) and has been used safely for more than a decade in a wide range of medical products. the company said.

Designed to minimize patient pain, the Mynx is deployed without the use of a suture or permanent metal implant, avoiding cinching or tugging of the artery often associated with other VCDs.. It immediately expands to three to four times its original size by rapidly absorbing the blood and fluids around the puncture site, sealing both the arteriotomy and the tissue tract. The sealant then dissolves naturally within 30 days, leaving nothing behind but a healed artery.

The Mynx can be used in a wide range of clinical cases typically not closed with existing closure devices. Preserving vessel integrity, the Mynx goes through the existing sheath, eliminating a sheath exchange and thereby avoiding potential tissue trauma and tract expansion. In addition, the Mynx sealant is delivered to the outside of the artery, leaving behind no intravascular components.

The Mynx Vascular Closure Device is FDA approved to close femoral arterial puncture sites for both diagnostic and interventional procedures.

October 2008

Related Content

Vascade MVP Reduces Time to Ambulation Follow EP Procedures
News | Vascular Closure Devices | November 11, 2018
The Vascade MVP vascular closure system met its endpoints compared to manual compression in a pivotal clinical study...
Technology | Vascular Closure Devices | November 05, 2018
November 2, 2018 — Cordis, a Cardinal Health company, today announced the U.S.
Teleflex Acquires Essential Medical
News | Vascular Closure Devices | October 05, 2018
Teleflex Inc. announced the acquisition of Essential Medical Inc. Based in Exton, Pa., Essential Medical is a privately...
Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial
News | Vascular Closure Devices | May 10, 2018
Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the...
Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial
News | Vascular Closure Devices | February 21, 2018
Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional...
The bioresorbable Cordis Mynx Grip vascular closure device seals arteriotomies without use of permanent hardware.

The bioresorbable Cordis MynxGrip vascular closure device seals arteriotomies without use of permanent hardware.

Feature | Vascular Closure Devices | January 22, 2018 | Dave Fornell
While manual compression remains the gold standard for hemostasis of catheterization vascular access site arteriotomi
Vivasure Enrolls First Patient in Frontier IV Clinical Trial
News | Vascular Closure Devices | December 29, 2017
Vivasure Medical announced in October the successful enrollment of the first patient in the Frontier IV clinical study...
Enrollment Completed in U.S. IDE Trial for Manta Large Bore Vascular Closure Device
News | Vascular Closure Devices | December 22, 2017
Essential Medical announced the completion of enrollment in the U.S. pivotal investigational device exemption (IDE)...
Overlay Init